Lab Manager | Run Your Lab Like a Business

Product News

Bruker Introduces scimaX™ MRMS for Novel Phenomics Workflows

Bruker introduces the game-changing scimaXTM Magnetic Resonance Mass Spectrometer (MRMS)

by Bruker Corporation
Register for free to listen to this article
Listen with Speechify
0:00
5:00

scimaXAt the 66th ASMS Conference, Bruker announced innovative mass spectrometry products and workflows for breakthroughs in life science research, in clinical research, and large-cohort validations in phenomics and proteomics, in novel biopharma applications, and in applied toxicology and forensics markets.

Frank H. Laukien, PhD, commented: “We believe that our new products and novel workflows shown at ASMS 2018 will fundamentally change life science research by mass spectrometry. The new scimaX system is designed to enable high-throughput phenomics by extreme resolution magnetic resonance mass spectrometry. The revolutionary timsTOF™ Pro with online PASEF is already opening new research fields in ultra-high sensitivity and high-throughput proteomics. I am convinced that both technologies will play important roles in enabling true clinical phenomics and clinical proteomics, which over time may well have a similar impact on the practice of medicine as next-generation sequencing.”

Phenomics and Proteomics Innovations

Bruker introduced the game-changing scimaXTM Magnetic Resonance Mass Spectrometer (MRMS). The scimaX MRMS delivers industry-leading mass resolution exceeding 20 million (R > 20,000,000), in a smaller footprint and without the need for any liquid cryogens. Bruker’s novel conduction-cooled Maxwell™ magnet technology essentially makes the magnet "invisible," and allows the use of highest-performance MRMS in standard mass spectrometry laboratories.

Get training in Biosafety and Biosecurity and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Biosafety and Biosecurity Course

This extreme MRMS resolution allows isotopic fine structure (IFS) analysis to easily determine exact elemental formulae in complex mixtures, without any chromatography. Using this unique capability, the scimaX enables the novel workflow of flow injection analysis (FIA-MRMS) for large cohort, high-throughput phenomics studies with up to 200 samples per day. Biopharma users can perform advanced native protein and fragment-based drug discovery studies using MRMS, which has recently been called a “bona-fide” platform for native protein analysis in the scientific literature. With an optional MALDI source, pharma customers have demonstrated the exceptional capabilites of MRMS for label-free MS imaging for PK/PD studies in drug development.

Dr. Steve Gross, professor at Weill Cornell Medicine, said: “Bruker's new scimaX MRMS system is a game-changer for ultrahigh-resolution mass spectrometry. By eliminating the burden and costs of liquid cryogen fills and lab renovations as a barrier to instrument installation, scimaX is available to any MS lab in need of maximal mass resolution to answer high-impact scientific questions.”

Bruker’s revolutionary timsTOF™ Pro for next-generation proteomics uses four dimensions (4-D) of separation in this unique nLC-TIMS-MS/MS instrument. It combines proprietary, dual Trapped Ion Mobilitiy Spectrometry (TIMS) using the just published online PASEF method1, which has the potential to dramatically improve high-throughput and ultra-high sensitivity proteomics. The timsTOF Pro, has been further enhanced for ASMS, and is now also compatible with MaxQuant v1.6.2.0, and PEAKS Studio v8.5 for protein identification (ID), label-free quantitation (LFQ), and tandem mass tag (TMT) workflows. Rapid development by third-party software collaborators is enabled by Bruker’s open file format, and several additional groups are developing timsTOF Pro compatibility into their software suites.

Also new is full integration with the Evosep One (www.evosep.com) separation device with Bruker’s Hystar LC/MS control for high-throughput clinical proteomics of up to 200 samples per day. This novel combination delivers superb sensitivity (50 ng HeLa) and high throughput for LFQ of ~1,200 proteins in only ~5 minutes.

Dr. Tadashi Yamamoto, director of the Biofluid Biomarker Center (BBC), and Emeritus Professor at Niigata University in Japan, stated: “I was impressed with the sensitivity of the timsTOF Pro PASEF workflow. It could routinely identify a low-level C-peptide in urine that other vendors could not easily identify. This critical advance in sensitivity was a key factor for my decision to introduce this new technology in my laboratory.”

Dr. Gary Kruppa, Bruker’s VP of Proteomics, added: “We are pleased that the high sensitivity PASEF workflow is being validated by our proteomics customers. It is also attracting biopharma applications for host cell protein (HCP) characterization, as higher sensitivity allows for the identification of more proteins that were previously not identified. Given its industry-leading robustness due to its orthogonal source and dual-TIMS funnel, the timsTOF Pro has the potential to become the preferred workhorse for high sensitivity HCP characterization in biopharma.”